News Release

Adamis Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference

SAN DIEGO, CA--(Marketwired - Jun 6, 2014) -Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that it will present at the 9th Annual JMP Securities Healthcare Conference at The Westin New York Grand Central on Wednesday, June 25, 2014. President and CEO, Dr. Dennis Carlo, is scheduled to present at 12:30 p.m. Eastern Time.

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. The company's current specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease, and APC-3000, an HFA inhaled nasal steroid product for the treatment of allergic rhinitis. The company's vaccine product candidates and cancer drug product candidates under research and development include TeloB-VAX, a cell-based therapeutic cancer vaccine and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer.


Adamis Contact

Mark Flather
Director, Investor Relations &
Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951